Henry Lowman, Ph.D., Chief Scientific Officer, will be presenting at the Molecular Med Tri-Con 2012 in San Francisco on February 19, 2012. The title of the presentation is “Proteolytically Activated Antibodies have the Potential to Expand Therapeutic Index and Open Up New Target Space.”
Sean McCarthy, DPhil, Chief Executive Officer, will be presenting at the BioTech Showcase in San Francisco on January 9, 2012.
Henry Lowman, Ph.D., Chief Scientific Officer will be presenting at the IBC Antibody Engineering / Therapeutics Conference in San Diego on December 6, 2011.
Building a Culture of Innovation
PharmaVoice, Special Issue: Year in Preview, November/December 2011
Sean McCarthy, DPhil, comments on Innovation in special issue of PharmaVoice.
Read Article (pdf)
CytomX Therapeutics will be presenting at BioEurope – 2011 in Dusseldorf, Germany on Tuesday, November 1, 2011.
Henry Lowman, Ph.D., Chief Scientific Officer will be presenting at the Human Antibodies and Hybridomas Conference in Cannes, France November 7-9, 2011.
CytomX Therapeutics will be presenting on a panel at BioNetwork West in Laguna Niguel, CA October 24-26, 2011.
CytomX Therapeutics Promotes Henry Lowman, Ph.D., to Chief Scientific Officer
Read Press Release (pdf)
CytomX Announces Appointment of Sean McCarthy as Chief Executive Officer
Read Press Release (pdf)
Nancy Stagliano, PhD, CEO will present at BIO International Convention June 27-30, 2011 in Washington, DC at the Washington Convention Center, Dupont Circle Room, Tuesday, June 28, 2011, 10:45 am EDT.
Dr. Henry Lowman, VP of Research, will present on June 22, 2011 at the Next Generation Protein Therapeutics Summit in San Francisco, CA.
January 5, 2011
CytomX Therapeutics Appoints Sean McCarthy as Chief Business Officer
McCarthy Brings Diverse Deal and Strategic Experience; New Appointment Further Strengthens CytomX Leadership Team
Read Press Release (pdf)
November 19, 2010
CytomX Therapeutics Announces Key R&D Leadership Appointments
Mark Rolfe, Ph.D., Named Chief Scientific Officer and Henry Lowman, Ph.D., Named Vice President
of Research
Read Press Release (pdf)
November 12, 2010
CytomX Therapeutics Awarded Two Federal Research Grants under the Qualifying Therapeutic Discovery Project (QTDP) Program
Grants Support Development of Probodies™ in Oncology Indications
Read Press Release (pdf)
September 23, 2010
CytomX Therapeutics Completes $30 Million Series B Financing
Proceeds to Advance Platform of Proteolytically-activated Antibody Therapies;
Backed by Third Rock Ventures, Roche Venture Fund
Read Press Release (pdf)
Dr. Nancy Stagliano, CEO, will present an update on Probodies at the PEGS meeting in Boston, MA on May 21, 2010.
Dr. Nancy Stagliano, CEO, will present on Oct. 8, 2009 at the 3rd Annual Therapeutic Monoclonal Antibody Discovery conference in Boston, MA.
Dr. James West will present on Oct. 8 in Hanover, Germany at the PEGS Europe meeting.
CytomX Therapeutics receives a second Phase I SBIR award from the NIH/NCI to
discover and develop a Probody to the Epidermal Growth Factor Receptor
(EGFR).
CytomX Therapeutics to present at the PepTalk conference in Coronado, CA on January 13 and 16.
Drs. Dennis Fenton and Gary Wilcox join CytomX’s Board of Directors.
CytomX Therapeutics completes an Exclusive License Agreement with the University of California, Santa Barbara, to its core intellectual property.
Dr. James West joins the company as Head of Research.
CytomX Therapeutics receives a Phase I SBIR award from the NIH/NCI to further its work on anti-angiogenic peptides.
CytomX Therapeutics, LLC is founded as a subsidiary of CytomX, LLC. Dr. Nancy Stagliano is appointed Chief Executive Officer.
